Affordable Access

Introduction of cyclofem once-a-month injectable contraceptive in Mexico.

Authors
  • Garza-Flores, J
  • Moraks del Olmo, A
  • Fuziwara, J L
  • Figueroa, J G
  • Alonso, A
  • Monroy, J
  • Perez, M
  • Urbina-Fuentes, M
  • Guevara, S J
  • Cedeno, E
  • Barrios, R
  • Ferman, J J
  • Medina, L M
  • Velazquez, E
  • Perez-Palacios, G
Type
Published Article
Journal
Contraception
Publisher
Elsevier
Publication Date
Jul 01, 1998
Volume
58
Issue
1
Pages
7–12
Identifiers
PMID: 9743890
Source
Medline
Keywords
License
Unknown

Abstract

The effectiveness and continuation rates associated with the once-a-month injectable contraceptive Cyclofem were investigated in an introductory trial conducted in three Mexican provinces (Sinaloa, Guanajuato, and Veracruz). Cyclofem contains 25 mg of medroxyprogesterone acetate and 5 mg of estradiol cypionate. A total of 3457 women (640 women from rural communities and 2817 from urban and suburban family planning centers) were enrolled and 20,316 woman-months of treatment experience were accumulated during the 12-month study period. The mean age of study participants was 23.6 years; 70% had previously used at least one contraceptive method. There was only one pregnancy (rate, 0.03%). The overall life-table continuation rate at 1 year was 26.1%, but this rate was higher in the community-based group (36.9%) than in the health center group (22.4%). This discrepancy is presumed to reflect the greater access of clinic clients to other contraception options. Continuation was highest among women 30-34 years of age, those with low levels of education, women with five or more children, and those who did not want more children. Only 14% of discontinuations were method-related. The 1-year discontinuation rate for bleeding problems, including amenorrhea, was 10.2%. These findings indicate Cyclofem is a safe, effective method appropriate for inclusion in Mexico's Ministry of Health Family Planning Program.

Report this publication

Statistics

Seen <100 times